AZD9668: Pharmacological characterization of a novel oral inhibitor of neutrophil elastase

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 313-320

  Stevens, T ^a   Ekholm, K ^a   Granse M ^a   Lindahl, M ^a   Kozma, V ^a   Jungar, C ^a   Ottosson, T ^a   Falk Hakansson H ^a   Churg, A ^b   Wright, J L ^b   Lal, Harbans ^a   Sanfridson, A ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 9668; CIGARETTE SMOKE; ELASTASE; FRESELESTAT; INTERLEUKIN 1BETA; SERINE PROTEINASE; SIVELESTAT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LUNG HEMORRHAGE; LUNG INJURY; LUNG LAVAGE; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SMOKE;

ACUTE LUNG INJURY; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMPHYSEMA; FEMALE; GLYCINE; GUINEA PIGS; HUMANS; KINETICS; LEUKOCYTE ELASTASE; MICE; MICE, INBRED BALB C; OXADIAZOLES; PNEUMONIA; PROTEIN BINDING; PYRIDONES; PYRIMIDINONES; RATS; SERINE PROTEINASE INHIBITORS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; SULFONAMIDES; SULFONES; SWINE; TOBACCO SMOKE POLLUTION;

EID: 80053169347     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.182139     Document Type: Article

References (40)

1. 1-Antitrypsin Deficiency, in Chronic Obstructive Pulmonary Disease (Stockley RA, Rennard SI, Rabe K, and Celli B eds) pp 447-459, Blackwell Publishing Limited, Boston, MA.
2. Beatty K, Bieth J, and Travis J (1980) Kinetics of association of serine proteinases with native and oxidized α-1-proteinase inhibitor and α-1-antichymotrypsin. J Biol Chem 255:3931-3934.
3. Bédard M, McClure CD, Schiller NL, Francoeur C, Cantin A, and Denis M (1993) Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol 9:455-462.
4. Bergin DA, Greene CM, Sterchi EE, Kenna C, Geraghty P, Belaaouaj A, Belaaouaj A, Taggart CC, O'Neill SJ, and McElvaney NG (2008) Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem 283:31736-31744.
5. Betsuyaku T, Nishimura M, Yoshioka A, Takeyabu K, Miyamoto K, and Kawakami Y (1996) [Neutrophil elastase and elastin-derived peptides in BAL fluid and emphysematous changes on CT scans]. Nihon Kyobu Shikkan Gakkai Zasshi 34(Suppl):69-74.
6. Bhowmik A, Seemungal TA, Sapsford RJ, and Wedzicha JA (2000) Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.Thorax 55:114-120. (Pubitemid 30245950)
7. + transport. Am J Physiol Lung Cell Mol Physiol 288:L813-L819.
8. Chan SC, Shum DK, and Ip MS (2003) Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. Am J Respir Crit Care Med 168:192-198. (Pubitemid 36920973)
9. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Churg A, Wang R, Wang X, Onnervik PO, Thim K, and Wright JL (2007) Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 62:706-713. (Pubitemid 47235016)
11. Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, Fallahnejad M, and Weinbaum G (1986) Immunolocalization of elastase in human emphysematous lungs. J Clin Invest 78:482-493. (Pubitemid 16074086)
12. Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, and Entwistle N (2011) Effect of the oral neutrophil elastase inhibitor, AZD9668, in patients with cystic fibrosis, at the 107th Annual Conference of the American Thoracic Society; 2011 May 13-18; Denver, CO. May 13-18, 2011. American Thoracic Society, New York.
13. Gottlieb DJ, Stone PJ, Sparrow D, Gale ME, Weiss ST, Snider GL, and O'Connor GT (1996) Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 154:1290-1295. (Pubitemid 26391171)
14. Gunawardena K, Gullstrand H, and Perrett J (2010) Safety, tolerability and pharmacokinetics of AZD9668, an oral neutrophil elastase inhibitor, in healthy subjects and patients with COPD, at the European Respiratory Society Annual Congress; 2010 Sept 18-22; Barcelona, Spain. Abstract 1163, 203s. European Respiratory Society, Lausanne, Switzerland.
15. Hayakawa M, Katabami K, Wada T, Sugano M, Hoshino H, Sawamura A, and Gando S (2010) Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock 33:14-18.
16. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645-2653. (Pubitemid 38787999)
17. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, and Miyamoto T (1991) ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 177:814-820.
18. Laurell CB and Eriksson S (1963) The electrophoretic α-globulin pattern of serum in α-antitrypsin deficiency. Scand J Clin Invest 15:132-140.
19. Liou TG and Campbell EJ (1995) Nonisotropic enzyme-inhibitor interactions: a novel nonoxidative mechanism for quantum proteolysis by human neutrophils. Biochemistry 34:16171-16177.
20. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, and Turino GM (2008) Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 32:1146-1157.
21. Luisetti M, Sturani C, Sella D, Madonini E, Galavotti V, Bruno G, Peona V, Kucich U, Dagnino G, Rosenbloom J, et al. (1996) MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 9:1482-1486. (Pubitemid 26233794)
22. Maryanoff BE, De Garavilla L, Greco MN, Haertlein BJ, Wells GI, Andrade-Gordon P, and Abraham WM (2010) Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med 181:247-253.
23. Morrison HM, Kramps JA, Burnett D, and Stockley RA (1987) Lung lavage fluid from patients with α1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci (Lond) 72:373-381. (Pubitemid 17012615)
24. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE, et al. (2004) Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 59:837-842. (Pubitemid 39389622)
25. Owen CA (2008) Leukocyte cell surface proteinases: regulation of expression, functions, and mechanisms of surface localization. Int J Biochem Cell Biol 40:1246-1272.
26. Owen CA, Campbell MA, Sannes PL, Boukedes SS, and Campbell EJ (1995) Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases. J Cell Biol 131:775-789.
27. Rubin H (1996) Serine protease inhibitors (SERPINS): where mechanism meets medicine. Nat Med 2:632-633.
28. Sinha S, Watorek W, Karr S, Giles J, Bode W, and Travis J (1987) Primary structure of human neutrophil elastase. Proc Natl Acad Sci U S A 84:2228-2232. (Pubitemid 17075844)
29. Stockley RA, Snell N, Perrett J, and Gunawardena K (2010) Efficacy and safety of AZD9668, an oral neutrophil elastase inhibitor, in idiopathic bronchiectasis, at the European Respiratory Society Annual Congress; 2010 Sept 18-22; Barcelona, Spain. Abstract 375, 38s. European Respiratory Society, Lausanne, Switzerland.
30. Stolk J, Veldhuisen B, Annovazzi L, Zanone C, Versteeg EM, Van Kuppevelt TH, Berden JH, Nieuwenhuizen W, Iadarola P, and Luisetti M (2005) Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z α-1-antitrypsin deficiency. Respir Res 6:47.
31. Tang M, Gu YJ, Wang WJ, Xu YP, and Chen CZ (2004) Effect of cardiopulmonary bypass on leukocyte activation: changes in membrane-bound elastase on neutrophils. Perfusion 19:93-99. (Pubitemid 38607511)
32. Tremblay GM, Vachon E, Larouche C, and Bourbonnais Y (2002) Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). Chest 121:582-588. (Pubitemid 34133001)
33. Van der Vaart H, Postma DS, Timens W, and ten Hacken NH (2004) Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 59:713-721. (Pubitemid 39061538)
34. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, and Fischer BM (1999) Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 276:L835-L843. (Pubitemid 29249637)
35. Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, and Taggart CC (2009) Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 183:8148-8156.
36. Wiedow O and Meyer-Hoffert U (2005) Neutrophil serine proteases: potential key regulators of cell signalling during inflammation. J Intern Med 257:319-328. (Pubitemid 40461184)
37. Wright JL, Farmer SG, and Churg A (2002) Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med 166:954-960. (Pubitemid 35193225)
38. Young RE, Voisin MB, Wang S, Dangerfield J, and Nourshargh S (2007) Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase-deficient mice. Br J Pharmacol 151:628-637. (Pubitemid 47016294)
39. Yurewicz EC and Zimmerman M (1977) Cytochalasin B-dependent release of azurophil granule enzymes from human polymorphonuclear leukocytes. Inflammation 2:259-264.
40. Zhou S, Chan E, Duan W, Huang M, and Chen YZ (2005) Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 37:41-213. (Pubitemid 40259715)